TW201695B - - Google Patents
Download PDFInfo
- Publication number
- TW201695B TW201695B TW081104408A TW81104408A TW201695B TW 201695 B TW201695 B TW 201695B TW 081104408 A TW081104408 A TW 081104408A TW 81104408 A TW81104408 A TW 81104408A TW 201695 B TW201695 B TW 201695B
- Authority
- TW
- Taiwan
- Prior art keywords
- treatment
- pct
- pseudo
- tyrosine
- uvb
- Prior art date
Links
- 230000035614 depigmentation Effects 0.000 claims abstract description 14
- 230000000699 topical effect Effects 0.000 claims abstract description 10
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 11
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 4
- 229910001424 calcium ion Inorganic materials 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000004215 Carbon black (E152) Substances 0.000 claims 1
- 229930195733 hydrocarbon Natural products 0.000 claims 1
- 150000002430 hydrocarbons Chemical class 0.000 claims 1
- 125000002577 pseudohalo group Chemical group 0.000 claims 1
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 1
- 239000002023 wood Substances 0.000 claims 1
- 208000012641 Pigmentation disease Diseases 0.000 abstract description 9
- 230000019612 pigmentation Effects 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 208000035475 disorder Diseases 0.000 abstract description 6
- 206010015150 Erythema Diseases 0.000 abstract description 5
- 231100000321 erythema Toxicity 0.000 abstract description 5
- 102000003425 Tyrosinase Human genes 0.000 abstract description 2
- 108060008724 Tyrosinase Proteins 0.000 abstract description 2
- 229910052723 transition metal Inorganic materials 0.000 abstract description 2
- 150000003624 transition metals Chemical class 0.000 abstract description 2
- 108010036322 pseudocatalase Proteins 0.000 abstract 3
- 206010047642 Vitiligo Diseases 0.000 abstract 1
- WMOSTDJFFWYKNF-UHFFFAOYSA-L hydrogen carbonate;manganese(2+) Chemical compound [Mn+2].OC([O-])=O.OC([O-])=O WMOSTDJFFWYKNF-UHFFFAOYSA-L 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 8
- 208000002741 leukoplakia Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- -1 peroxy anion Chemical class 0.000 description 7
- 239000006071 cream Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 241000519995 Stachys sylvatica Species 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 239000011572 manganese Substances 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 3
- 206010027982 Morphoea Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229910052748 manganese Inorganic materials 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 2
- PCWZKQSKUXXDDJ-UHFFFAOYSA-N Xanthotoxin Natural products COCc1c2OC(=O)C=Cc2cc3ccoc13 PCWZKQSKUXXDDJ-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000008309 hydrophilic cream Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000008099 melanin synthesis Effects 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108091071247 Beta family Proteins 0.000 description 1
- 229910000906 Bronze Inorganic materials 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000020564 Eye injury Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000006933 Hermanski-Pudlak Syndrome Diseases 0.000 description 1
- 206010071775 Hermansky-Pudlak syndrome Diseases 0.000 description 1
- 102100028902 Hermansky-Pudlak syndrome 1 protein Human genes 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- GZMKWMMWAHQTHD-UHFFFAOYSA-L [Mn++].OS([O-])(=O)=O.OS([O-])(=O)=O Chemical compound [Mn++].OS([O-])(=O)=O.OS([O-])(=O)=O GZMKWMMWAHQTHD-UHFFFAOYSA-L 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 239000010974 bronze Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- KUNSUQLRTQLHQQ-UHFFFAOYSA-N copper tin Chemical compound [Cu].[Sn] KUNSUQLRTQLHQQ-UHFFFAOYSA-N 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 238000007323 disproportionation reaction Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 238000010943 off-gassing Methods 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 238000002161 passivation Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000002468 redox effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002151 serous membrane Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- CADICXFYUNYKGD-UHFFFAOYSA-N sulfanylidenemanganese Chemical compound [Mn]=S CADICXFYUNYKGD-UHFFFAOYSA-N 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Transceivers (AREA)
- Mobile Radio Communication Systems (AREA)
Description
經濟部屮央櫺準局CX工消件合作杜印姐 201695 Λ 6 _Π_6_ 五、發明説明(1 ) 本發明有閧酪胺酸陽性色素脱失症之治療,待別可 用於治療白斑病。本發明提供該治療用之組成物,及該治 療方法。 白斑病是一種慢性色素脫失症,病人因局部色素缺失, 引起不雅觀的白斑或白點,又極易曬傷。雖病情不會使人 虛弱無力,但常使人心情沮喪。目前仍未知病因,推定偽 因自體色疫反應,神經糸統之涉入,或黑素細胞之中毒效 應所起。通常,唯一因應之道是使用將皮虜著色的化妝品 ,掩飾斑塊;至於黑人與印第安人,則使用脱色素劑,如 氫輥,脱除其餘色素沉著皮》的色素。採用所諝PUVA法治 療僅有若干有限的成功的報告。 PUVA法中,口服美索沙楞(methoxalen)(即8 -甲氣基索 拉楞(psoralen))或較少用之其它索拉楞類,漶而病人暴 露於UV A光下。索拉楞類是植物準出物,自古埃及時代已 知用作光敏化劑。索拉楞係經糸統性投藥,因此光敏作用 未限於局部;且因此種作用出現於UVA範圍(320-400 nm), 故病人日常生活需戴特製眼鏡,以防眼睛受傷。又復, PUVA之副作用包含噁心、紅斑、水腫、眩晕、頭痛、起水 皰、生成大疱、甲分離、痤瘡形發瘆,和皮庸疼痛睹重。 長期的危險包含皮虜癌,表皮萎縮.皮虜過早老化,内障 形成,和免疫条統改變。此種療法相信對正常淋巴細胞和 蘭氏細胞有毒性。因此,此種療法常限用於老年病人,或 限於兩年期限。近來,提議讓病人浸泡索拉楞浴,俾減輕 PUVA法之若干危險。 (請先閲請背而之注意亊項#蜞寫本頁) 本紙張尺度逍用中國國家楳準(CNS) T4規格(210X297公*) 3 81. 6. 10,000張(H) Π 6 五、發明説明(2 ) 經濟部屮央櫺準局Μ工消伢合作杜印製 其它酪胺酸誨-陽性色素脱失症包括赫曼斯基-布拉克症 候群(Hermansky-Pud lak Syndrome) 〇 今日,出人意外的發現白斑病和其它酪胺酸豳-陽性色素 脱失症,可藉著於局部施用重碩酸錳U)或其它偽觭豳後 ,讓病人暴露於UVB光(290 -320刪)下而獲得有效治療。又 復,發現藉該療法使色素沉著後,可藉局部施用偽觸_而 未暴露於UVB下,即可於患部保有該色素沉著水平至少歷 一段時間。 於同樣待審的專利申請案(優先申請日相同,對應於UK-A-9110651)中,吾人掲示偽觸誨可用於局部促成日光曜成 古銅色。 偽觸誨意指:於活體内可以類似觸_之方式,催化H202 的歧化作用之。漿膜透過性、生理可接受性化合物。 不欲受任何特定假說所束缚,相信白斑病和其它酪胺酸 酶-陽性色素脱失症僳因缺之觸缠所引起,該觸_允許黑 素細胞内之過氣陰離子濃度比正常值高。由於酪胺酸_被 過氧陰離子鈍化,1-酪胺酸藉酪胺酸誨催化氧化成1-多巴 (Ι-dopa)之反應受到抑制,而1-多巴正為黑素之生物合成 所必需者。又復,由於過氧陰離子藉光化學作用還原成羥 基離子,故伴隨著羥基離子的産量增加。 皮»暴露於UVB輻射下,産生超氣陰離子基園,此基圄 是人酪胺酸_的較佳_基(比氣優異40倍),故可促進黑素 之形成。然而,超氣陰離子基園被技化成二氧和過氣陰離 子,除非催化_或若干其它競爭機轉去除過氧陰離子,否 (請先閲讀背而之注意苹項#填寫本頁) 本紙張尺度遑用中a Β家楳準(CNS)甲4規格(210x297公龙)4 81. 6. 10,000張(H) 201695 Λ 6 Β6 經濟部屮央檁準局只工消赀合作社印蚁 五、發明説明(3) 則將導致羥基離子不合意地增高。如此,相信存在有偽觸 誨,可使其充分暴於UVB之下,生成超氣陰離子基画,可 促進觸媒缺乏部位的色素沉著,而未出現灼傷或其它細胞 傷害。 依本發明之第一主題,提供偽觸痗用於製造供酪胺酸鹵 -陽性色素脱失症治療用之局部用藥物之用法。 第二主題中,本發明提供一種局部用組成物,包括偽觸 ϋ及其生理可接受性局部用之載媒劑。 第三主題中,本發明提供一種偽觸誨.其用於治療酪胺 酸_-陽性色素脫失症。 第四主題中,本發明提供一種治療酪胺酸痗-陽性色素 脱失症之方法,包括至少對病人皮虜的色素脫失部位,施 用有效量之偽觸痴,随後,將接受處理後的皮膚暴於UVB 光下,誘使色素脱失部位的黑素生成。 如前述,本發明特別可應用於治療白斑病,但也可用於 治療其它酪胺酸誨-陽性色素脱失症,例如赫曼斯-布拉克 症候群。 偽觭誨為任何可催化過氣化氫的技化作用之生理可接受 性化合物。已知數種化合物,如重硪酸錳U)-鹽,為偽 觸_ ;而其它偽觸誨可藉簡單篩檢試驗決定。 目前較佳的偽觸痗是過渡金屬配位錯合物,其中電子接 受者,配位基的感應效應,可增強金颶對過氧化氫技化作 用的氧化還原效應。通常,金羼是Cu(I), Fe(E),或特 別為Mn(I),而配位基是重碩酸鹽。待好,偽觸_是錳 (請先閱請背而之注意苹項再项寫本頁) 裝- 線- h紙张尺度边用中8國家樣毕(CNS)甲4規格(210x297公*) g 81. 6. 10,000¾ (Η) 201695 Λ 6 Ιϊ 6 經濟部中央櫺準而只工消赀合作社印製 五、發明説明(4 ) (I )-重碩酸鹽錯合物。該錯合物易經由令氣化亞錳與過 量重磺酸鹽於水溶液接觸而製備。 偽觸豳調配於局部用載媒劑。便利地,載媒劑包括親水 乳霜,於其中加入偽觸痗的水性溶液或懸浮液,而形成乳 霜劑或洗劑。另外,載媒劑可為浴油,唯也可使用任何其 它相容的局部用載媒劑而獲得局部用組成物。 較好,組成物含有鈣離子,宜添加氦化鈣,而補償顯然 出現於白斑病皮虜的0缺乏。通常,鈣離子濃度為5至20 m η ο 1 〇 組成物可含有例如缓和劑、香料等局部用劑習用的成分。 通常,局部用組成物至少施用於皮虜的色素脱失部位, 常見施於皮虜合體表面,每曰兩次。兩次施藥中的至少一 次後,病人經短暫延遲,通常約20至60分鐘後,暴於UVB 光,全偽觸痗蓮送入表皮内。UVB暴光量有限,俥防止紅 斑,隨UVB忍受度的增加,最低紅斑劑量增高,UVB的暴光 量隨治療時間由數秒增至約5分鐘。療程持續數月,直至 先前色素脱失部位有可接受的色素沉著水平為止。隨後, 藉持缅每日施用局部用組成物,但可能頻率減少,而未暴 光UVB,可維持色素沉著。若患部又脱失色素,則推薦暴 於UVB光下長達色素恢復沉著所箱的時間。 藉下列非限制性實例説明本發明。 實例1 氛化亞錳(380mg)加至重磺酸鈉(2.3g)於純水(3.0Π义) 於周溫之溶液内。混合物放置至氣體之逸出停止為止。所 (請先閲-背而之注意亊項#项寫本頁) 本紙尺度逍用中B B家橒準(CNS)肀4規格(210x297公Λ) 6 81. 6. 10,000¾ (H) 201685 Λ 6 Π 6 經濟部中央櫺準局Α工消伢合作社印製 五、發明説明(5) 得帶粉紅的褐色液與親水乳霜(100g, VeMbase)混合製得 白色乳霜。 Veribase是種乳霜載媒劑,含有Macregol硬脂酸酯2000 ;硬脂醇;液髏石蜡;白軟石蝤;聚丙烯酸;氫氧化鈉; EDTA二鈉(即:乙撑二胺四乙酸二鈉鹽);甲基及丙基巴拉 本(即:4-羥基苯甲酸甲基及丙基酯);及水。 實例H 例I之白色乳霜每日二次(早展與下午或夜晚)施於數名 白斑病人的色素脱失部位(白斑斑點)。其中一次施藥後經 約2 0分鐘後,患部短時間暴於U V B光下而提供低於最低紅 斑劑量。隨著病人對UVB光線忍受度的增高,暴光時間由 數秒延長至長約5分鐘。各病例的白斑斑點經3至6個月的 療程後,皆出現顯著的色素沉著。 附圖I及I[顯示接受治療的白斑病人典型的改善。二圖 皆顯示同一病人耳。病人至診所求疹時,她患數增白斑病 大斑塊,包含右耳部位有一塊(第I圖)。經三個月如前述 的偽觸誨/UVB治療後,許多白斑塊,含右耳那一塊的大小 實質縮小(第E圖)。此病人又持續接受偽觸晦/UVB療法三 個月,此時,白斑塊的大小大體更進一步縮小。隨後,病 人即單雒持接受偽觸義ί療法。 實例Μ 使用添加氛化鈣成5ιπιηο1鈣離子含量的乳霜劑,重禊例 I之程序。18名病人的平均治療期為4.2個月;其中14名 呈現部分反應,2名顯現顯著的,但非完全的,白斑病皮 (請先閲請背而之注意事項再塡寫本頁) 本紙it尺度边用中a B家楳準(CNS)肀4規格(2】0X297公;it) 7 8】.6. 10,000¾ (Η) 201695 Λ 6 Π 6 五、發明説明(6 ) *部位色素沉著現象。 V I 例 實 複呈素 重皆色 , 體虜 劑全皮 霜.,部 乳月患 的25病 量2.斑 含為白 子期的 離療著 鈣治顯 01均示 IBQ平顯 10的者 得人一 而病任 鈣名無 化12但 氣 。, 加序 _ 。 添程反象 用之分現 使 I 部著 例現沉 (請先閲讀背而之注意事項再填寫本頁) 經濟部中央櫺準局β工消t合作杜印製 本紙張尺度逍用中B國家樣準(CNS)甲4規格(210X297公龙) 8 81. 6. 10,000¾ (H)
Claims (1)
- 烴濟部中央標準局员工消费合作社印製 A7 B7 C7 D7 82. 1. 1 9發在愈 六、申請專利範圍 1. 一種用於治療酪胺酸陽性色素脱失症之局部用藥 學組成物,包括一種MnU) -重碩酸鹽錯合物以做為偽觸 鹵及一種生理可接受性局部用載媒劑。 2. 如申請專利範圍第1項之組成物,其含有5至20mni〇l鈣 離子。 Mi, if α| I.----κ--.-------I --------裝-----.一訂- „ ..φ (請先閲讀背面之注意事項再塡寫本頁) . 木纸張又度適用中國國家標準(CN’S)甲4規格(210 X 297公紫)!
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB919110652A GB9110652D0 (en) | 1991-05-15 | 1991-05-15 | Composition and method of treating depigmentation disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201695B true TW201695B (zh) | 1993-03-11 |
Family
ID=10695131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW081104408A TW201695B (zh) | 1991-05-15 | 1992-06-04 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5433942A (zh) |
| EP (1) | EP0584171B1 (zh) |
| JP (1) | JPH06510275A (zh) |
| KR (1) | KR100190978B1 (zh) |
| AT (1) | ATE183097T1 (zh) |
| AU (1) | AU649543B2 (zh) |
| CA (1) | CA2102514A1 (zh) |
| DE (1) | DE69229780T2 (zh) |
| ES (1) | ES2137185T3 (zh) |
| GB (1) | GB9110652D0 (zh) |
| GR (1) | GR3031483T3 (zh) |
| IE (1) | IE69854B1 (zh) |
| IL (1) | IL101871A (zh) |
| MY (1) | MY108848A (zh) |
| NZ (1) | NZ242748A (zh) |
| PH (1) | PH30792A (zh) |
| SG (1) | SG45381A1 (zh) |
| TW (1) | TW201695B (zh) |
| WO (1) | WO1992020354A1 (zh) |
| ZA (1) | ZA923561B (zh) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7404967B2 (en) * | 1994-12-21 | 2008-07-29 | Cosmederm, Inc. | Topical product formulations containing strontium for reducing skin irritation |
| US6139850A (en) * | 1994-12-21 | 2000-10-31 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
| EP0799018A4 (en) * | 1994-12-21 | 2000-03-29 | Cosmederm Technologies | FORMULATIONS AND METHODS FOR REDUCING SKIN IRRITATION |
| BR9510478A (pt) | 1994-12-21 | 1998-12-15 | Cosmederm Technologies | Formulações e métodos para redução da irritação da pele |
| GB2307175A (en) * | 1995-11-14 | 1997-05-21 | Steifel Lab Inc | Topical composition comprising a transition metal and bicarbonate ions, particularly for the promotion of pigmentation |
| US6979327B2 (en) * | 2000-02-25 | 2005-12-27 | Mount Sinai School Of Medicine | Treatment of vitiligo |
| DE10043466A1 (de) * | 2000-09-04 | 2002-03-28 | Johannes Wohlrab | Manganverbindungen enthaltende Zubereitung zur topischen Applikation und deren Verwendungen |
| FR2814945B1 (fr) * | 2000-10-09 | 2003-02-14 | Oreal | Procede de traitement de la canitie |
| US6630130B1 (en) | 2001-07-16 | 2003-10-07 | Pearl Grimes | Sunless tanning cream |
| US20030224028A1 (en) * | 2002-05-13 | 2003-12-04 | Societe L'oreal S.A. | Metal complexes for promoting skin desquamation and/or stimulating epidermal renewal |
| FR2839449B1 (fr) * | 2002-05-13 | 2006-12-08 | Oreal | Utilisation d'au moins un complexe de metal comme desquamant |
| US20040148712A1 (en) | 2002-11-29 | 2004-08-05 | Francis Pruche | Composition for coloring a keratin material, comprising at least two components, and coloring processes |
| JP4687436B2 (ja) * | 2005-12-13 | 2011-05-25 | ウシオ電機株式会社 | エキシマ光治療器 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU71110A1 (zh) * | 1974-10-15 | 1976-11-11 | ||
| NZ188912A (en) * | 1977-12-01 | 1984-05-31 | Ici Australia Ltd | Prevention or treatment of copper deficiency by topical application of copper |
| AU518946B2 (en) * | 1979-02-23 | 1981-10-29 | Kenneth John Hausler | Trace mineral (s) cream |
| AU544544B2 (en) * | 1980-08-20 | 1985-06-06 | Erwin Gunther Walliczek | Cuprous complex for therapeutic use |
| NZ198416A (en) * | 1980-12-08 | 1984-07-31 | Bio Syst Res Inc | Anti-viral,anti-bacterial,and/or anti-fungal compositions containing metal oxycarboxylates |
| JPH0196107A (ja) * | 1987-10-07 | 1989-04-14 | Kanebo Ltd | 皮膚化粧料 |
| JPH02108612A (ja) * | 1988-10-19 | 1990-04-20 | Shizen:Kk | 二価三価複合鉄塩配合化粧品 |
| EP0424033A3 (en) * | 1989-10-19 | 1991-07-31 | Pola Chemical Industries Inc | External skin preparation |
-
1991
- 1991-05-15 GB GB919110652A patent/GB9110652D0/en active Pending
-
1992
- 1992-05-14 IL IL10187192A patent/IL101871A/xx not_active IP Right Cessation
- 1992-05-14 MY MYPI92000812A patent/MY108848A/en unknown
- 1992-05-15 PH PH44350A patent/PH30792A/en unknown
- 1992-05-15 EP EP92910389A patent/EP0584171B1/en not_active Expired - Lifetime
- 1992-05-15 ZA ZA923561A patent/ZA923561B/xx unknown
- 1992-05-15 SG SG1996005300A patent/SG45381A1/en unknown
- 1992-05-15 AU AU17854/92A patent/AU649543B2/en not_active Ceased
- 1992-05-15 CA CA002102514A patent/CA2102514A1/en not_active Abandoned
- 1992-05-15 WO PCT/GB1992/000878 patent/WO1992020354A1/en not_active Ceased
- 1992-05-15 NZ NZ242748A patent/NZ242748A/xx unknown
- 1992-05-15 KR KR1019930703445A patent/KR100190978B1/ko not_active Expired - Fee Related
- 1992-05-15 AT AT92910389T patent/ATE183097T1/de not_active IP Right Cessation
- 1992-05-15 ES ES92910389T patent/ES2137185T3/es not_active Expired - Lifetime
- 1992-05-15 DE DE69229780T patent/DE69229780T2/de not_active Expired - Fee Related
- 1992-05-15 JP JP4510487A patent/JPH06510275A/ja active Pending
- 1992-05-15 US US08/150,014 patent/US5433942A/en not_active Expired - Fee Related
- 1992-06-04 TW TW081104408A patent/TW201695B/zh active
- 1992-07-01 IE IE921559A patent/IE69854B1/en not_active IP Right Cessation
-
1999
- 1999-10-08 GR GR990402575T patent/GR3031483T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GR3031483T3 (en) | 2000-01-31 |
| GB9110652D0 (en) | 1991-07-03 |
| ZA923561B (en) | 1993-04-28 |
| EP0584171A1 (en) | 1994-03-02 |
| EP0584171B1 (en) | 1999-08-11 |
| IE69854B1 (en) | 1996-10-02 |
| CA2102514A1 (en) | 1992-11-16 |
| DE69229780T2 (de) | 1999-12-16 |
| IL101871A (en) | 1997-01-10 |
| NZ242748A (en) | 1995-01-27 |
| AU649543B2 (en) | 1994-05-26 |
| MY108848A (en) | 1996-11-30 |
| KR100190978B1 (ko) | 1999-06-15 |
| WO1992020354A1 (en) | 1992-11-26 |
| DE69229780D1 (de) | 1999-09-16 |
| US5433942A (en) | 1995-07-18 |
| PH30792A (en) | 1997-10-17 |
| IE921559A1 (en) | 1992-11-18 |
| IL101871A0 (en) | 1992-12-30 |
| ES2137185T3 (es) | 1999-12-16 |
| AU1785492A (en) | 1992-12-30 |
| SG45381A1 (en) | 1998-01-16 |
| JPH06510275A (ja) | 1994-11-17 |
| ATE183097T1 (de) | 1999-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0584178B1 (en) | Composition and method of enhancing sun tanning | |
| TW201695B (zh) | ||
| FR2543437A1 (fr) | Composition pour regenerer le collagene du tissu conjonctif de la peau et son procede de preparation | |
| KR101072133B1 (ko) | 피부 미백 효능을 상승시키는 화장료 조성물 | |
| CN101102746B (zh) | 包含笃斯越桔提取物的皮肤增白除皱组合物及其制备方法 | |
| HU9400833D0 (en) | Process for making cosmetic and sunburn compositions | |
| CA2414247C (en) | Cosmetic composition and method comprising a hydroxamate mmpi and a triterpenoid glycoside | |
| HK1258583A1 (zh) | 皮肤美白化妆品 | |
| AU2001273115A1 (en) | Cosmetic composition and method | |
| JPH05213736A (ja) | 皮膚化粧料 | |
| CA2268030A1 (en) | A process for stabilizing levogyre ascorbic acid (laa) and stable laa compositions | |
| JP2002370962A (ja) | 美白用化粧料および皮膚老化防止・改善用化粧料 | |
| US7468195B2 (en) | Skin treatment preparation | |
| US20040185127A1 (en) | Cosmetic composition and method | |
| JPH08113525A (ja) | 美白用皮膚外用剤 | |
| KR102847522B1 (ko) | 오존화 오일을 포함하는 미백용 기능성 패치 | |
| JPH10167924A (ja) | キトサン誘導体含有メラニン生成促進剤 | |
| JPH05221834A (ja) | 白髪の防止及び白髪黒色化用毛髪化粧料 | |
| JPH07165553A (ja) | メラニン原因症予防治療剤 | |
| TWI281866B (en) | Anti-oxidative sunscreen composition | |
| HK1055673B (zh) | 皮膚治療製劑 | |
| HK1055673A1 (zh) | 皮膚治療製劑 | |
| RO121364B1 (ro) | Loţiune pentru calmarea arsurilor solare | |
| RO121403B1 (ro) | Loţiune după ras |